{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-23-000053","form_type":"8-K/A","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.691393+00:00","generated_at":"2026-06-11T16:51:27.405943+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Supernus Q2 2023 revenues $135.5M, down 20% YoY; GAAP operating loss $17.6M","bullets":["Qelbree net sales $31.0M (+179%), GOCOVRI $28.8M (+17%) in Q2 2023 vs Q2 2022.","Trokendi XR net sales fell 73% in Q2 and 60% in H1 2023 due to generic erosion.","GAAP net loss ($0.8M) or ($0.02)/diluted share; adjusted operating earnings $10.0M vs $37.6M.","Cash & securities $189.1M at June 30, 2023, down from $555.2M due to $402.5M note repayment.","Full-year 2023 guidance reaffirmed: total revenue $580-$620M, GAAP operating loss $(30)-$(10)M."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-23-000053","json":"https://secwatch.observer/filing/0001356576-23-000053.json","markdown":"https://secwatch.observer/filing/0001356576-23-000053.md","text":"https://secwatch.observer/filing/0001356576-23-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000053/0001356576-23-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000053/supn-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T16:51:27.405943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"161a0a16a29209d5b6bdeb5d9d58b4b439b3a6c6","claim":"SUPERNUS PHARMACEUTICALS, INC. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release announcing its results of operations and financial condition for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000053/0001356576-23-000053-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}